CN110869369A - 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 - Google Patents

五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 Download PDF

Info

Publication number
CN110869369A
CN110869369A CN201880033034.7A CN201880033034A CN110869369A CN 110869369 A CN110869369 A CN 110869369A CN 201880033034 A CN201880033034 A CN 201880033034A CN 110869369 A CN110869369 A CN 110869369A
Authority
CN
China
Prior art keywords
piperidinyl
piperazinyl
amino
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880033034.7A
Other languages
English (en)
Other versions
CN110869369B (zh
Inventor
邓贤明
王洪睿
曾涛玲
张婷
姜婷婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Publication of CN110869369A publication Critical patent/CN110869369A/zh
Application granted granted Critical
Publication of CN110869369B publication Critical patent/CN110869369B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

本发明涉及药物化学领域，五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用。具体地，涉及一类具有通过特异性地增强Ras蛋白泛素化降解的化合物，其制备方法、包含该化合物的药物组合物，以及这些化合物在制备用于预防或治疗与生物体内与Ras活性相关的疾病的药物中的用途，尤其是在制备用于预防或***生长与转移的药物中的用途。
Figure DDA0002278202600000011

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201880033034.7A 2017-05-19 2018-05-17 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 Active CN110869369B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710357938.2A CN108948002A (zh) 2017-05-19 2017-05-19 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN2017103579382 2017-05-19
PCT/CN2018/087336 WO2018210314A1 (zh) 2017-05-19 2018-05-17 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Publications (2)

Publication Number Publication Date
CN110869369A true CN110869369A (zh) 2020-03-06
CN110869369B CN110869369B (zh) 2022-06-28

Family

ID=64273371

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710357938.2A Pending CN108948002A (zh) 2017-05-19 2017-05-19 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN201880033034.7A Active CN110869369B (zh) 2017-05-19 2018-05-17 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710357938.2A Pending CN108948002A (zh) 2017-05-19 2017-05-19 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Country Status (6)

Country Link
US (1) US11292787B2 (zh)
EP (1) EP3626718B1 (zh)
JP (2) JP7145873B2 (zh)
CN (2) CN108948002A (zh)
AU (1) AU2018269275B2 (zh)
WO (1) WO2018210314A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948002A (zh) 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
WO2019143991A1 (en) * 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CN108546731A (zh) * 2018-04-27 2018-09-18 厦门大学 调节Ras泛素化的方法
WO2020102686A1 (en) * 2018-11-16 2020-05-22 California Institute Of Technology Erk inhibitors and uses thereof
WO2020168963A1 (zh) * 2019-02-18 2020-08-27 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
WO2023155866A1 (zh) * 2022-02-18 2023-08-24 四川海思科制药有限公司 一种吡唑并吡啶衍生物及其在医药上的应用
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014368A1 (en) * 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
WO2006058120A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
CN101014597A (zh) * 2004-04-02 2007-08-08 沃泰克斯药物股份有限公司 可用作rock和其他蛋白激酶抑制剂的吖吲哚
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
WO2017025868A1 (en) * 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
WO2007076423A2 (en) * 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
EP2001880A2 (en) * 2006-03-07 2008-12-17 Array Biopharma, Inc. Heterobicyclic pyrazole compounds and methods of use
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2011123937A1 (en) 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
EP3269714A1 (en) * 2016-07-13 2018-01-17 Netherlands Translational Research Center B.V. Inhibitors of tryptophan 2,3-dioxygenase
CN108948002A (zh) 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN108546731A (zh) * 2018-04-27 2018-09-18 厦门大学 调节Ras泛素化的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014368A1 (en) * 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
CN101014597A (zh) * 2004-04-02 2007-08-08 沃泰克斯药物股份有限公司 可用作rock和其他蛋白激酶抑制剂的吖吲哚
WO2006058120A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
WO2017025868A1 (en) * 2015-08-10 2017-02-16 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BASHANDY, MAHMOUD SAYED等: "《1-(4-(Pyrrolidin-1-ylsulfonyl)phenyl)ethanone in heterocyclic synthesis:》", 《INTERNATIONAL JOURNAL OF ORGANIC CHEMISTRY》 *
STN: "《1H-Pyrrole-2-sulfonamide, N-[(2,4-dichlorophenyl)methyl]-5-(1H-pyrazolo[3,4-b]pyridin-3-yl)- (CA INDEX NAME)》", 《REGISTRY数据库（STN）》 *
STN: "《1H-Pyrrole-2-sulfonamide, N-[(4-methoxyphenyl)methyl]-5-(1H-pyrazolo[3,4-b]pyridin-3-yl)- (CA INDEX NAME)》", 《REGISTRY数据库（STN）》 *
STN: "《Benzamide, N-(phenylmethyl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)- (CA INDEX NAME)》", 《REGISTRY数据库（STN）》 *
STN: "《Methanone, [5-(1H-indol-3-yl)-2-furanyl]-4-morpholinyl- (CA INDEX NAME)》", 《REGISTRY数据库（STN）》 *
STN: "《Methanone, 1-pyrrolidinyl[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]- (CA INDEX NAME)》", 《REGISTRY数据库（STN）》 *
STN: "《Methanone,1-piperidinyl[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl]- (CA INDEX NAME)》", 《REGISTRY数据库（STN）》 *

Also Published As

Publication number Publication date
JP7410087B2 (ja) 2024-01-09
AU2018269275B2 (en) 2021-04-01
EP3626718A4 (en) 2021-03-03
CN110869369B (zh) 2022-06-28
CN108948002A (zh) 2018-12-07
EP3626718A1 (en) 2020-03-25
JP2021176853A (ja) 2021-11-11
JP2020520890A (ja) 2020-07-16
US11292787B2 (en) 2022-04-05
AU2018269275A1 (en) 2019-12-19
WO2018210314A1 (zh) 2018-11-22
EP3626718B1 (en) 2024-05-15
US20200172521A1 (en) 2020-06-04
JP7145873B2 (ja) 2022-10-03

Similar Documents

Publication Publication Date Title
CN110869369B (zh) 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
CN113365988B (zh) Shp2抑制剂及其应用
US11787801B2 (en) Protein kinase inhibitors, preparation method and medical use thereof
CN113544128A (zh) Kras-g12c抑制剂
KR102429355B1 (ko) 티에노피리미딘 화합물, 그의 제조 방법, 약학 조성물 및 용도
CN106220644B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN115057855B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
CN115515947B (zh) Shp2抑制剂及其组合物和应用
CN103459382B (zh) 用于抑制pask的杂环化合物
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN104910137A (zh) Cdk激酶抑制剂
CN110770234A (zh) 取代芳基醚类化合物、其制备方法、药用组合物及其应用
CN113717156A (zh) Egfr抑制剂、其制备方法及用途
CN111909108A (zh) 联苯类化合物及其制备方法和医药用途
WO2020221006A1 (zh) 一种bet蛋白抑制剂、其制备方法及用途
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
US10807983B2 (en) Imidazo-fused heterocycles and uses thereof
CN115785088A (zh) 作为sos1抑制剂的化合物及其应用
JP2022542449A (ja) Ｓｔａｔ３二機能性リン酸化部位を標的とするトリアロマティック化合物のクラスおよびその応用
CN113773273B (zh) 苯并异噻唑类化合物及其制备方法和用途
CN112851679B (zh) 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用
WO2024032661A1 (zh) Kif18a抑制剂及其用途
CN117794923A (zh) 苯并二噁烷类化合物、其制备方法与应用
CN116891502A (zh) Egfr降解剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant